OM Pharma is a global Geneva-based biopharmaceutical company. It is a leader in the prevention of recurrent respiratory and
urinary tract infections, also active in the treatment of vascular diseases.
It operates worldwide through a strong network of international partners and continues to invest into R&D to develop immunotherapeutic products addressing acute and chronic immunological disorders resulting from infections and inflammation.
OM Pharma is operating to highest Good Manufacturing Practice (GMP) standards which rely on a high level of Biotech competencies and experienced teams.
The company strives to help patients around the world to live better lives by allowing access to a better management
of immunological imbalances.
For more information, please visit www.ompharma.com